AR118471A1 - Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2 - Google Patents

Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2

Info

Publication number
AR118471A1
AR118471A1 ARP200100803A ARP200100803A AR118471A1 AR 118471 A1 AR118471 A1 AR 118471A1 AR P200100803 A ARP200100803 A AR P200100803A AR P200100803 A ARP200100803 A AR P200100803A AR 118471 A1 AR118471 A1 AR 118471A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
alkoxy
substituted
independently
Prior art date
Application number
ARP200100803A
Other languages
English (en)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR118471A1 publication Critical patent/AR118471A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos de fórmula (1), y sales farmacéuticamente aceptables de estos, donde a, b, R², R³, R⁴, R⁵, R⁸, R⁹, X¹, X⁶ y X⁷ se definen en la memoria descriptiva. Esta descripción también hace referencia a materiales y métodos para la preparación de compuestos de fórmula (1), a composiciones farmacéuticas que los contienen y a su uso para el tratamiento de enfermedades, trastornos y afecciones asociados con RIPK2. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable este donde: a es un enlace simple, b es un enlace doble, X¹ es NR¹N y R² es oxo; o a es un enlace doble, b es un enlace simple, X¹ se selecciona de N y CR¹C y R² se selecciona de hidrógeno, alquilo C₁₋₄ y alcoxi C₁₋₄; R¹C se selecciona de hidrógeno, halo y alquilo C₁₋₆ que se sustituye con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo, hidroxi, ciano, alcoxi C₁₋₄ y amino que se sustituye opcionalmente con uno o dos alquilos C₁₋₄; R¹N se selecciona de alquilo C₁₋₄, cicloalquilo C₃₋₈-(CH₂)ₙ, heterociclilo C₂₋₈-(CH₂)ₙ y heteroarilo C₁₋₉-(CH₂)ₙ, donde cada uno de los restos de alquilo C₁₋₄, cicloalquilo C₃₋₈, heterociclilo C₂₋₈ y heteroarilo C₁₋₉ se sustituye con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo, hidroxi, ciano, alquilo C₁₋₄, alcoxi C₁₋₄ y amino que se sustituye opcionalmente con uno o dos alquilos C₁₋₄, y donde cada uno de los sustituyentes opcionales de alquilo C₁₋₄ y alcoxi C₁₋₄ se sustituye independientemente con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; n se selecciona de 0, 1, 2 y 3; R³ es alquilo C₁₋₆ que se sustituye con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo, hidroxi, ciano, alcoxi C₁₋₄ que se sustituye opcionalmente con alcoxi C₁₋₄, y de amino que se sustituye opcionalmente con uno o dos alquilos C₁₋₄, donde uno o más de los átomos de hidrógeno de R³ pueden ser opcionalmente deuterio; cada uno de R⁴ y R⁵ se selecciona independientemente de hidrógeno, halo y alquilo C₁₋₄; X⁶ se selecciona de N y C(R⁶); X⁷ se selecciona de N y C(R⁷); cada uno de R⁶ y R⁷ es independientemente hidrógeno, halo, alquilo C₁₋₄ y alcoxi C₁₋₄; R⁸ se selecciona de hidrógeno, halo, alquilo C₁₋₄ y alcoxi C₁₋₄, donde los sustituyentes de alquilo C₁₋₄ y alcoxi C₁₋₄ se sustituyen con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; y R⁹ se selecciona de alquilo C₁₋₆, cicloalquilo C₃₋₈, heterociclilo C₂₋₈ y heteroarilo C₁₋₉, cada uno sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo, hidroxi, ciano, oxo, alquilo C₁₋₄, alcoxi C₁₋₄ y amino que se sustituye opcionalmente con uno o dos alquilos C₁₋₄, donde cada uno de los sustituyentes opcionales de alquilo C₁₋₄ y alcoxi C₁₋₄ se sustituye independientemente con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; y donde cada uno de los restos de heterociclilo y heteroarilo tiene independientemente de 1 a 4 miembros anulares que son heteroátomos, y cada uno de los heteroátomos se selecciona independientemente de N, O y S.
ARP200100803A 2019-03-22 2020-03-20 Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2 AR118471A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962822734P 2019-03-22 2019-03-22

Publications (1)

Publication Number Publication Date
AR118471A1 true AR118471A1 (es) 2021-10-06

Family

ID=70285980

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100803A AR118471A1 (es) 2019-03-22 2020-03-20 Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2

Country Status (3)

Country Link
AR (1) AR118471A1 (es)
TW (1) TW202102498A (es)
WO (1) WO2020198053A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022178559A1 (en) * 2021-02-22 2022-08-25 The Trustees Of Princeton University 2-substituted bicyclo[1.1.1]pentanes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
BR112019003320B1 (pt) * 2016-09-15 2024-02-20 Boehringer Ingelheim International Gmbh Compostos de heteroaril carboxamida, sal farmaceuticamente aceitável dos mesmos, composição farmacêutica e seus usos como inibidores de ripk2

Also Published As

Publication number Publication date
TW202102498A (zh) 2021-01-16
WO2020198053A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
AR107714A1 (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR119424A1 (es) Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp
AR113964A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa
AR120080A1 (es) Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
AR112834A1 (es) Derivados de rapamicina
AR119018A1 (es) Inhibidores de proteína quinasas dependientes de adn
AR117424A1 (es) Inhibidores de los receptores erbb
AR127309A2 (es) Derivados de piridazinona
AR119728A1 (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2
AR119657A1 (es) Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos
AR109709A1 (es) Inhibidores de la fosfatidilinositol 3-quinasa
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR121078A1 (es) Derivados de arilamida con actividad antitumoral
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR114793A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
AR088565A1 (es) Inhibidor de cetp de oxazolidinona biciclico fusionado
AR098666A1 (es) Compuestos de biarilacetamida y sus métodos de uso
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR090955A1 (es) Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del vih
AR104878A1 (es) MODULADORES DE ROR GAMMA (RORg)
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
AR116464A1 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
AR119971A1 (es) Derivados de piridazin-3(2h)-ona fusionados con azol
AR126693A1 (es) Compuestos de pirazolopiridinona

Legal Events

Date Code Title Description
FB Suspension of granting procedure